Patent: 8,278,109

Summary for Patent: 8,278,109

Title:	Hyperglycosylated hCG detection device
Abstract:	The present invention related to a pregnancy test device that can selectively detect hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample. The sample can be deposited on a proximal portion of the device for transport to a distal portion of the device. The device can include a release medium formed of a first material and including a detectable label thereon and a capture medium, including a capture site, in fluid communication with the release medium and formed of a second, different material. At least one of the release medium and the capture medium includes a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H.
Inventor(s):	Nazareth; Albert R. (Mercerville, NJ), Snowden; Timothy (Howell, NJ)
Assignee:	Church & Dwight Co., Inc. (Princeton, NJ)
Application Number:	12/704,892
Patent Claims:	see list of patent claims

US Patent 8,278,109: Claims on hCG-H Selective Detection and Pregnancy Viability Readouts

US Patent 8,278,109 is drafted around point-of-care immunoassay architectures that discriminate hyperglycosylated human chorionic gonadotropin (hCG-H) from regular hCG, using a two-stage solid-phase design (a release medium upstream and a capture medium downstream) and, in some embodiments, a scavenger to suppress cross-reactivity. The patent also claims diagnostic methods that equate detection of hCG-H to “high probability of successful implantation” and a “viable pregnancy.”

This analysis (i) maps the independent claim themes to the dependent claim fallback structure you would expect in claim-construction disputes, (ii) identifies the core novelty levers the drafter relies on, and (iii) translates the claim language into practical design-around and validity risk vectors that matter for competitors and investors.

---

What are the operative claim themes?

1) Two-material, two-stage immunoassay flow: release medium + capture medium

The core device premise in the claim set is a test element where:

• A liquid sample is deposited on a proximal portion and transported to a distal portion.
• A release medium (material A) contains a detectable label and binding chemistry.
• A capture medium (material B, different from A) contains immobilized binding sites that generate the final selective signal.

This is explicit across claim families:

• Claim 1 requires release medium with a labeled conjugate and a first binding member, plus a capture medium with a second binding member immobilized on the capture medium. It additionally constrains affinity/selectivity allocation: only the second binding member must exhibit the moderate-to-high affinity and preferential reactivity with hCG-H.
• Claims 3-8 add a scavenger component between sample deposit and capture to remove regular hCG signal interference.
• Claims 20-28 implement dual-analyte capture architectures (hCG-H site and regular hCG site).
• Claims 29-35 establish a common fluid path with two capture media (hCG-H and regular hCG capture) and distinct release formulations/coupled components.

2) Affinity/selectivity “allocation” is a key constraint

Across multiple dependent chains, the patent does not merely require hCG-H selectivity. It assigns where selectivity must be expressed.

• Claim 1: “it is only the second binding member that exhibits the moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H.”
• Claims 5, 11, 23 repeat variations where at least one binding member with moderate to high affinity must be preferential for hCG-H.
• Claims 16-18 adds a quantitative composition lever: hCG-H-selective binding members must be >50% of total binding members on the release medium.

This is a litigation-relevant drafting strategy: it creates a boundary condition that can be exploited if an accused device distributes affinity characteristics differently between label/release binding and immobilized capture binding.

3) Two major anti-cross-reactivity mechanisms

The claim set describes two separate ways to avoid regular hCG dominating the signal:

1. Spatial selectivity via binding chemistry placement
   The “only the second binding member” concept (claim 1) and variants (claims 16, 20-28) aim to force hCG-H discrimination at the immobilized capture site.

2. A scavenger located upstream of capture (regular hCG neutralization)

   • Claim 3 requires a scavenger component selectively preferentially reactive with regular hCG, positioned between sample deposit and capture.
   • Claims 6-8, 12-14 define multiple placement zones (up to/including labeled conjugate region; between conjugate and capture; any capture-medium upstream region).

This creates practical enforcement leverage because competitors often omit scavengers or place them differently (and placement may be material to claim coverage).

4) Diagnostic method claims tie hCG-H detection to “viable pregnancy”

The patent also claims methods where:

• A device from the device claims is used.
• A liquid sample potentially contains regular hCG and/or hCG-H.
• The method detects hCG-H presence and concludes viable pregnancy via “high probability of successful implantation.”

These appear identically across multiple method claims:

• Claims 2, 15, 19, 28, 35 (and structurally similar ones within the set).
  This kind of claim language is often where enforceability and validity arguments cluster (classification, medical utility, and whether the “viability” interpretation is overly broad relative to the assay readout).

---

How do the claim families differ, claim-by-claim?

A) Family anchored on “only capture binding has hCG-H moderate-to-high affinity”

Claim 1 is the anchor:

• Release medium: first material + labeled conjugate + first binding member reactive with hCG-H or hCG epitope.
• Capture medium: second material + capture site with second binding member immobilized reactive with hCG-H or hCG epitope.
• Constraint: at least one binding member has moderate-to-high affinity and selective reactivity with hCG-H, but “only the second binding member” has this moderate-to-high affinity and selectivity.

Critical implication: an accused product where the high-affinity discrimination exists on the release/reagent binding and not the immobilized capture binding is a potential non-infringement path.

B) Family with scavenger component to suppress regular hCG

Claims 3-14:

• Release medium includes detectable label; capture medium includes capture sites.
• A scavenger component reactive with regular hCG is placed between sample deposit and capture (claim 3), then constrained by placement sub-claims (claims 6-8, 12-14).

Critical implication: a scavenger may be required for infringement if the accused device lacks a regular hCG scavenger. Even if it uses affinity discrimination, the presence/absence and location of scavenger is a hard factual question.

C) Family with dual reagent groups and a “>50% hCG-H-selective binding member” ratio

Claims 16-18:

• Release medium comprises two groups of labeled conjugates:
  • Group 1: binding member selectively preferentially reactive with regular hCG.
  • Group 2: binding member selectively preferentially reactive with hCG-H with moderate-to-high affinity.
• Quantitative constraint: hCG-H-selective binding members are >50% of total binding members on the release medium.

Critical implication: claim coverage depends on composition ratios. A competitor can potentially shift composition so the hCG-H-selective binding fraction is 50% or lower, avoiding the literal ratio requirement.

D) Family with dual capture sites on the capture medium: hCG-H and regular hCG

Claims 20-28:

• Release medium has binding members for both analyte classes (hCG-H affinity/moderate-high selectivity plus regular hCG binding).
• Capture medium includes:
  • first capture site binds hCG-H
  • second capture site binds regular hCG
• Sub-claims (22-27) add common epitope binding, capturable component formats, and streptavidin/biotin alternatives.

Critical implication: if an accused system uses a common capture matrix without distinct capture sites, or uses multiplexing via different formats, these claims may narrow.

E) Family with a common fluid path and two capture media

Claims 29-35:

• Device comprises a common fluid path.
• At least one release medium in fluid communication with the common path.
• First capture medium selectively binds hCG-H.
• Second capture medium binds regular hCG.
• Sub-claims specify release medium composition (claim 30), capturable component (claim 31-32), and a single release medium embodiment (claim 33).

Critical implication: a competitor that removes the dual capture-media architecture (or uses a single capture zone) can seek an argument of non-infringement.

---

What are the strongest leverage points in the claim language?

1) “Only the second binding member” (Claim 1)

This is the most crisp and litigable specificity in the set. It forces the hCG-H discrimination’s moderate-to-high affinity selectivity to reside in the capture immobilized binding member, not the release/reagent binding member.

Business-grade readout:

• If an accused product’s strongest hCG-H affinity is implemented on the labeled conjugate side, Claim 1 is an enforcement risk for the patentee.
• If an accused product implements high-affinity discrimination at immobilized capture, Claim 1 aligns.

2) Scavenger component requirement and placement (Claims 3, 6-8, 12-14)

These sub-claims are position-dependent. A competitor can reduce risk by:

• omitting scavenger entirely, or
• relocating the scavenger outside the claimed regions, or
• using a different suppression mechanism than regular hCG scavenging.

3) The quantitative release ratio (>50% hCG-H binding members) (Claim 16)

This gives a clean literal design-around vector:

• If a competitor’s formulation sets the hCG-H-selective binding fraction at 50% or less, Claim 16 should fail literal reading.

4) Dual capture media + common fluid path (Claims 29-34)

A competitor that uses a single capture medium with multiple binding sites rather than separate capture media may avoid these claims depending on how “second material” and “first/second capture medium” are construed.

---

What is the patent landscape likely to look like (claim-level, not bibliographic)?

Without a full bibliographic record for the patent’s prosecution history and citation graph, the most reliable landscape conclusions must be claim-driven:

Near-neighbor technologies that commonly overlap

1. Lateral flow assays (LFAs) for hCG and pregnancy markers
2. hCG variants immunoassays that target hyperglycosylated hCG (hCG-H) or glycoforms
3. Two-site sandwich immunoassay structures with labeled reagent and immobilized capture
4. Cross-reactivity suppression via scavengers, competing binders, or blocked binding sites
5. Multiplex capture for analyte discrimination (hCG vs hCG-H)

US 8,278,109 is structured so that some of these common elements are not enough alone. The claim set insists on specific allocations:

• which binding member carries the moderate-to-high affinity and selectivity,
• whether a scavenger exists and where,
• whether >50% of release binding is hCG-H selective,
• whether capture architecture uses separate capture media/sites.

Most likely novelty disputes

The highest likelihood validity challenges, based on claim structure, tend to focus on:

• whether prior art already disclosed hCG-H selective binding in lateral flow or similar immunoassay platforms,
• whether scavengers for regular hCG in the context of hCG-H discrimination were already disclosed,
• whether dual capture for regular hCG and hCG-H using a common fluid path was already standard.

In many immunoassay cases, novelty is tied to:

• the specific combination,
• the allocation of selectivity/affinity between labeled reagent and capture immobilization,
• and the quantitative or positional constraints.

---

Claim-to-design translation: how competitors can steer around

Non-infringement design vectors against Claim 1

• Move the moderate-to-high affinity hCG-H selectivity from the capture binding member to the labeled conjugate binding member.
• Ensure the immobilized capture binding does not “exhibit” the required moderate-to-high affinity selectivity with hCG-H (in the literal sense asserted).

Design vectors against the scavenger claims (3-14)

• Remove the regular hCG scavenger component.
• Use a different cross-reactivity control method (for example, a competing binder that binds regular hCG but is not a “scavenger component” as claimed, depending on construction).
• Keep any “regular hCG scavenger” outside the claimed placement zones relative to sample deposit, conjugate region, and capture site.

Design vectors against the >50% constraint (16-18)

• Reduce the proportion of hCG-H-selective binding members on the release medium so it is not “greater than 50%” of total binding members.

Design vectors against dual capture media (29-34)

• Replace dual capture media with a single capture medium that supports both hCG-H and regular hCG capture in a combined zone.
• Remove the “common fluid path” plus first/second capture media architecture depending on how those are construed.

---

Investment and R&D implications

1) Patentee enforcement posture is likely claim-selective

Given the tight feature constraints (affinity allocation, scavenger placement, quantitative fraction, dual capture media), enforcement is likely to concentrate on products that use:

• scavenger-based suppression, and/or
• dual capture architectures for both regular hCG and hCG-H,
• and on formats where capture-site binding is where the hCG-H selectivity is implemented.

2) The largest technical risk for competitors is “feature creep”

If an accused product uses:

• a labeled conjugate designed for hCG-H plus high-affinity capture binding and
• a regular hCG scavenger in the correct position and
• a formulation where hCG-H-selective binding dominates the release medium,

the claim overlap risk rises quickly because multiple dependent claim elements reinforce the same architecture.

3) The method claims create separate commercial risk

Even if device claims narrow to specific architectures, the method claims attach to any use that:

• evaluates viability by detecting hCG-H presence in a liquid sample and
• interprets presence as high probability of implantation/viable pregnancy.

Commercialization of clinical claims, labeling language, and intended-use strategy can become part of the infringement analysis because “wherein the detected presence of hCG-H indicates…” is part of the claimed method logic.

---

Key Takeaways

• US 8,278,109 is built around lateral-flow-style two-stage immunoassay architecture with a release medium upstream and a capture medium downstream made of different materials.
• The most enforceable claim mechanics are: (i) affinity/selectivity allocation to the capture binding member only (Claim 1), (ii) a regular hCG scavenger component with defined location (Claims 3-14), and (iii) a formulation ratio constraint where hCG-H-selective binding members exceed 50% (Claims 16-18).
• A second layer of claim coverage depends on capture architecture: either dual sites (Claims 20-28) or dual capture media in a common fluid path (Claims 29-34).
• The pregnancy viability method claims are structured as a direct interpretive linkage: detecting hCG-H presence is treated as viability/implantation probability (Claims 2, 15, 19, 28, 35), raising distinct commercialization and intended-use exposure.

---

FAQs

1) What is the single most important novelty constraint in Claim 1?

That only the second binding member (immobilized on the capture medium) exhibits the moderate-to-high affinity and selective/preferential reactivity with hCG-H (Claim 1).

2) Do the claims require a scavenger?

Only the scavenger-containing device family does (Claims 3-14). Other families implement selectivity without a scavenger.

3) Can a competitor avoid Claim 16 without changing binders entirely?

Yes, by changing formulation so that hCG-H-selective binding members on the release medium are not “greater than 50%” (Claim 16).

4) What structural element most directly maps to assay hardware layout?

The split between release medium and capture medium (and their separate materials) plus whether the capture side uses two capture media (Claims 29-34) or dual capture sites (Claims 20-28).

5) How do method claims affect commercialization?

They link hCG-H detection to a clinical interpretation of viability/high implantation probability, so intended-use statements and diagnostic workflow can be material to the method infringement analysis (Claims 2, 15, 19, 28, 35).

---

References

[1] United States Patent 8,278,109.

Details for Patent 8,278,109

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	8,278,109	2030-02-12
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	8,278,109	2030-02-12
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	8,278,109	2030-02-12
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	8,278,109	2030-02-12
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	8,278,109	2030-02-12